Business Wire

OR-LATTICE-SEMICONDUCTOR

25.8.2021 22:02:13 CEST | Business Wire | Press release

Share
Lattice Certus-NX FPGAs Optimized for Automotive Applications

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today expanded its growing portfolio of automotive products with the announcement of versions of the Lattice Certus™-NX FPGA family optimized for infotainment, advanced driver assistance systems (ADAS), and safety-focused applications. Built on the Lattice Nexus™ platform, these new Certus-NX devices combine automotive-grade features with best-in-class I/O density, power efficiency, small size, reliability, instant-on performance, and support for fast PCI Express (PCIe) and Gigabit Ethernet interfaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005002/en/

“Demand for automotive semiconductors is increasing as the ongoing trends towards automotive system electrification, autonomy, and connectivity have manufacturers looking for ways to deliver the advanced features and user experiences drivers are looking for in their next vehicle,” said Jay Aggarwal, Director of Silicon Product Marketing, Lattice Semiconductor. “With class-leading performance and power efficiency, support for popular I/O standards in a small form factor, and high reliability, our Certus-NX general purpose FPGAs make a compelling silicon platform for the next-generation automotive applications car makers are eager to provide to their customers.”

“As more automotive systems go digital, modern cars have essentially become mobile datacenters. Automotive developers need access to secure and reliable silicon solutions with fast I/O performance to ensure mission-critical automotive systems can perform their functions instantaneously,” said K. Ganesh Rao, Practice Head – FPGA Solutions, Tata Elxsi. “Lattice Certus-NX FPGAs provide the reliability, performance, and feature set we need to make tomorrow’s automotive applications possible.”

The latest Certus-NX FPGAs are ideal for automotive applications like motor control, LED control in in-vehicle infotainment (IVI) systems, in-vehicle networking (IVN), and sensor data co-processing in ADAS applications. Key features of Certus-NX FPGAs include:

  • Low power consumption – Up to 4X lower power use than similar FPGAs, with a programmable back bias that enables user-selectable high performance or low power operating modes, depending on the needs of the application.
  • Small form factor – Up to 3X smaller with up to 2X the I/O density per mm2 in comparison to similar competing FPGAs.
  • Instant-on performance – Ultra-fast device configuration from SPI memory up to 12X faster than similar competing FPGAs, with individual I/O able to configure in just 3 ms, and full-device startup in only 8-14 ms, depending on device capacity.
  • Robust I/O interfacing capability – Lattice’s extensive Certus-NX I/O IP library includes:
    • 1.5 Gbps differential I/O with performance up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3.
  • Automotive certification and high reliability – Certus-NX FPGAs are AEC-Q100 qualified and provide up to 100X better soft error rate (SER) performance than similar FPGAs.
  • Authentication and encryption – To protect bitstreams against unauthorized access, Certus-NX FPGAs support AES-256 encryption with ECDSA; they are currently the smallest FPGAs on the market to support ECDSA.
  • Ease of use/design – Lattice Radiant® and Lattice Propel™ software tools help simplify and accelerate automotive system design. Certus-NX FPGAs are also supported by the Lattice mVision™ and Lattice sensAI™ solution stacks so designers can leverage the stacks’ modular hardware platforms, reference designs, neural network IP cores, and custom design services to accelerate automotive vision system design.

Automotive-grade versions of Certus-NX FPGAs are now sampling with select customers. For more information about the Lattice technologies mentioned above, please visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye